课题基金 / 基金详情

GENE THERAPY OF CORONARY ARTERY DISEASE

GENE THERAPY OF CORONARY ARTERY DISEASE
冠状动脉疾病的基因治疗
批准号:
5200352
负责人:
M C CAPOGROSSI
金额:
$0.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:

项目摘要

项目成果

M C CAPOGROSSI的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Our studies are aimed at evaluating whether gene therapy with replication-deficient, recombinant adenovirus vectors can be used to induce angiogenesis and restore blood supply to ischemic tissues and to prevent and treat restenosis after angioplasty. For the studies on angiogenesis, we have constructed adenoviral vectors which carry the cDNA for different angiogenic growth factors: VEGF165, aFGF1-154, recombinant secreted aFGF1-154 modified by the addition of the signal peptide for secretion from FGF-4, bFGF, PD-ECGF. The vectors which carry the cDNAs for VEGF and for aFGF induce endothelial cell proliferation and differentiation in vitro as well as angiogenesis in vivo when coinjected sucutaneously with reconstituted basement membrane proteins (Matrigel) in mice. Further, preliminary results show that autologous endothelial cells infected ex vivo with AdCMV.VEGF165 and subsequently injected into the iliac artery supplying the ischemic limb in a rabbit model of hindlimb ischemia induce angiogenesis in vivo. The construction of the remaining vectors has been completed only recently and the vectors are being evaluated for their biologic effects in vitro. For the studies on restenosis after angioplasty we have constructed adenoviral vectors which may act through one of the following steps: (1) selectively enhance endothelial cell regrowth at the site of vascular injury. (AdCMV.VEGF165 and AdCMV.PDECGF).(2) induce vascular smooth muscle cell death or growth arrest.(AdCMV.WAF-1, AdCMV.IGF1R-AS and AdCMV.MKP-1). In addition an adenovirus vector which carries the cDNA for human wild type p53 has been obtained from Dr. Vogelstein (Johns Hopkins University). (3) inhibit vascular smooth muscle cell migration from the media to the intima (AdCMV.TIMP-2). The above vectors are presently being evaluated to determine their biologic effects in vitro. Preliminary results show that AdCMV.p53 inhibits vascular smooth muscle cells (VSMC) proliferation while AdCMV.TIMP-2 inhibits VSMC invasion in the Boyden chamber.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
GENE THERAPY OF CORONARY ARTERY DISEASE
  • 批准号:
    3745552
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    M C CAPOGROSSI
  • 依托单位:
MECHANISMS OF ABNORMAL AUTOMATICITY IN CARDIAC PREPARATIONS
  • 批准号:
    3821461
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    M C CAPOGROSSI
  • 依托单位:
EFFECT OF ALPHA-ADRENERGIC STIMULATION ON ISOLATED VENTRICULAR MYOCYTES
  • 批准号:
    3817601
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    M C CAPOGROSSI
  • 依托单位:
GENE THERAPY TO INDUCE THERAPEUTIC ANGIOGENESIS
  • 批准号:
    2565760
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    M C CAPOGROSSI
  • 依托单位:
国内基金
海外基金
ROBO4对视网膜血管生成(angiogenesis)的调控及其分子机制
  • 批准号:
    81200692
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    23.0万元
  • 批准年份:
    2012
  • 负责人:
    陈凌
  • 依托单位: